Elan Reaches $203M Settlement with DOJ over Zonegran Marketing
Elan Pharmaceuticals Inc. has agreed to pay $203 million to resolve a federal probe into illegal marketing of the epilepsy drug Zonegran.
Elan Pharmaceuticals Inc. has agreed to pay $203 million to resolve a federal probe into illegal marketing of the epilepsy drug Zonegran.
The FDA has issued an alert to notify healthcare professionals that Zonegran, which is also available as generic zonisamide, can cause metabolic acidosis side effects in some patients. This blood…